Clinical Trial Update: A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the immunogenicity and safety of three RSV vaccine dose concentrations in infants and toddlers; the trial has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV vaccine (respiratory syncytial virus vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: RSV Immunisation | Phase 3 | Status: TERMINATED